Introduction
Focal epilepsy comprises simple and complex partial as well as secondarily generalized seizures and represents the most common form of epilepsy [1] . Epidemiological studies show that, akin to early childhood, the incidence of epilepsy peaks in the elderly population [2] . For most patients, epilepsy represents a life-long condition, and more than 50 million people are affected worldwide [3] . Monotherapy with antiepileptic drugs (AEDs) is the first-line treatment for partial-onset seizures (POS), however, more than one third of the patients show inadequate seizure control under monotherapy and thus require AED-combination regimens [4] [5] [6] . In addition, treatment dissatisfaction, low compliance and adherence are major reasons for sustained insufficient seizure control [7, 8] . Adverse events, due to poor AED tolerability profiles or inacceptable toxicities due to drug-drug interactions of AEDs with combination partners, as well as other concomitant medications [9] , are among the main determinants of low treatment adherence and impaired quality of life (QoL). This highlights the need for additional add-on therapy options that will benefit these patients not only in terms of seizure control, but also tolerability, adherence, lack of interactions with other medications, and QoL.
Zonisamide was introduced in Europe in 2005 for adjunctive therapy of POS, with or without secondary generalisation. It is currently licensed as adjunctive therapy for POS in patients 6 years and older and as monotherapy for the treatment of POS in adult patients with newly diagnosed epilepsy. The antiepileptic mechanisms of action of ZNS, while still not completely understood, are thought to be mediated through its action on voltage-sensitive sodium and calcium channels, as well as through modulation of GABAergic signaling [10] .
The efficacy and safety of ZNS as adjunctive therapy for the treatment of refractory POS have been investigated in randomized controlled trial settings in the United States and Europe. The duration of these trials was up to 36 weeks with active ZNS treatment dosing either once or twice daily. In total, 845 patients with treatment-refractory POS with or without secondary generalisation, were randomized in these trials, and the findings demonstrated that ZNS was generally well tolerated and efficacious as adjunctive therapy in these patients [11] [12] [13] [14] , with a recommended dose range for maintenance therapy between 300 and 500 mg/d. However, patients in controlled clinical trial settings are usually suffering from more severe and treatmentrefractory disease, and interventional studies do not allow for individualized dosing regimens. Thus, the aim of the present observational study ZOOM was to gain a broader clinical real-life practice insight on the use and retention of ZNS add-on therapy at earlier treatment stages in adult patients, and to investigate potential differential effects of ZNS in combination with different baseline AEDs.
Patients and methods
This open-label, observational study with zonisamide as add-on treatment in adult patients with POS, was performed in 38 centers across 4 European countries between 28 March 2012 and 15 July 2013. The majority of centers were located in Germany; Norway, Denmark and Sweden each contributed one site. The trial was registered in www.clinicaltrials.gov (NCT01830868), and had been subject to regulatory and ethical approval in all countries involved.
Study participation was offered to adult patients with POS whose epilepsy was insufficiently controlled with a current antiepileptic monotherapy, and thus required addition of ZNS to their antiepileptic regimen according to the physicians' clinical judgment. No further selection criteria with regard to patients' treatment history were applied.
The patients' seizure situation was to be assessed based on patient diaries, other written information sources, or patient interviews. The decision to prescribe ZNS was made by the physicians independently of their decision to include the patients into the study. Treatment was to be applied as per recommendation in the ZNS Summary of Product Characteristics (SmPC).
Patients undergoing off-label therapy with ZNS, patients who had started ZNS treatment more than 2 weeks prior to enrollment, or who concomitantly suffered from severe psychiatric disorders, were excluded from participation.
Upon the patient signing informed consent, baseline data on demographics, medical history, previous antiepileptic therapy, reason for ZNS prescription and concomitant medication and diseases were collected, and the physicians were to record the planned titration schedule for ZNS add-on therapy. In addition, patients were asked to complete a health related quality of life questionnaire (Quality of Life in Epilepsy Inventory-10; QOLIE-10) [15] ; the QOLIE-10 was applied for a subset of sites where it was used in routine clinical practice and was available and validated in local language. The QOLIE-10 consists of 10 questions about aspects of health and daily activities that could potentially be negatively affected by epilepsy and its treatment. Questions refer to the previous 4 weeks. Lower values of the score reflect better quality of life [15] .
Intermediate assessment was expected to be performed at about 3 months, the final assessment at about 6 months after the baseline visit. However, due to the non-interventional character of the study, no exact visit windows could be defined, and the visit schedule was up to the physician's discretion.
The primary endpoint was the retention rate of ZNS after 6 months from baseline. Secondary endpoints encompassed tolerability, patient-reported efficacy over 3 month intervals (again based on patient diaries, other written information, or patient interviews), ZNS and concomitant AED dosage, and QOLIE-10 score. In addition, subgroup analysis of ZNS retention rate and reported efficacy was performed according to age, class of concomitant AED medication, as well as the number of previously discontinued AED regimens [6, 16] ).
Statistical analysis
Descriptive statistical analyses were performed for all patients who had completed informed consent, received at least one dose of ZNS, and had at least one post-dose safety assessment (evaluable patients). Quantitative variables were analyzed by means of basic statistical parameters, while qualitative and ordinal scaled variables were presented by means of absolute and relative frequency distributions. Relative frequencies were based on the number of available data, i.e. excluding missing data. No imputation methods of missing values were applied to the data. Additionally, two sided 95%-confidence intervals (CI) were calculated for the retention rates over 3 and over 6 months, respectively. For subgroup analyses, patients were classified according to gender, age ( 60 years, >60 years) and the number of discontinued AED regimens within the last 5 years prior to baseline. Patients were further classified with respect to their concomitant baseline AED into the following 4 subgroups: carbamazepine or oxcarbazepine (CBZ + OXC), levetiracetam (LEV), lamotrigine (LTG) and valproate (VPA). Seven patients taking other than the above AEDs were subsumed under a ''Various'' class, and are not shown in the present manuscript. Changes in QOLIE-10 scores were also analyzed in dependency of the patients' seizure outcome at the 6-months visit by means of ANCOVA, with baseline QOLIE-10 level as covariate. Due to the exploratory nature of this analysis, no correction of multiple testing was performed.
All analyses were performed with the SAS1 package, version 9.2 (SAS Institute, Cray, NC, USA).
Results

Baseline description of patient population
Initially, it was planned to include 700 patients in the study. However, due to slow recruiting, this number of patients could not be achieved. Recruitment was stopped after the inclusion of the first 100 patients, of which 93 were evaluable, i.e. they had received at least one dose of ZNS, and had at least one post-dose safety assessment. Of these, 93 attended the baseline and 3-month follow-up visits, and 81 the 6-month follow-up visit. The mean duration of study participation was 181.8 days (range 19-337 days); mean duration until attending the 3-months visit was 93.9 days, and 189.2 days until attending the 6-months visit.
The gender distribution was balanced (46.2% male), the median age was 46 years (range 19-87); 25.8% of the patients were older than 60 years. The mean time since the initial diagnosis of epilepsy with POS was 13.4 years for all patients, and this time was shorter for patients who were older than 60 years (median: 7.5 years) than for younger patients (median: 10.6 years). The seizure situation over 3 months prior to baseline is shown in Table 1 and Fig. 1 . Almost one third (29.1%) of patients suffered from more than one seizure type (Fig. 1B) . Four patients were documented as free of seizures at baseline.
For 55 patients (59.1%), there was a documentation of at least one AED being discontinued during the last 5 years before enrolment into the study; of these, 26 patients (28.0%) had exactly one, 16 patients (17.2%) had two, and 13 patients (14.0%) had 3 or more discontinued AED regimens documented. Only 9 out of 24 patients (37.5%) who were older than 60 years had any documented discontinued AED during the last 5 years. In contrast, this was the case for 66.7% (46 out of 69 patients) of the younger patients.
Dosing of ZNS as add-on therapy
The main reason for prescribing ZNS add-on therapy was the lack of efficacy of AED monotherapy (90.3%), followed by adverse events caused by previous AED treatment (10.8%). The median planned first target dose of ZNS was 200 mg/d (range: 50-400 mg/ d), without marked differences between age groups. In 83.9% of the patients, the target dose was achieved after a mean of 33.2 days (SD AE 27.5 days), and within a mean of 2.6 titration steps (SD AE 1.5 steps; range: 1-7 steps). The number of titration steps was not affected by patients' age. The mean maximal dose reached after titration was 229.0 mg/d (AE116.9 mg); the minimal posttitration dose reported was 25 mg/d. Dose changes after achieving the target dose were reported for 17 patients (18.3%): for 9 patients, a dose reduction was documented, and for 8 a dose increase. The mean number of dose changes was 2.2 AE 1.6 (range: 1-6 dose changes) (not shown). Subgroup analysis according to age showed a lower mean post-titration ZNS dosage in patients older than 60 years (mean AE SD: 185.3 AE 47.7 mg/d), compared to younger patients (mean AE SD: 229.2 AE 111.0 mg/d).
Antiepileptic drug medication at baseline
All patients were to receive concomitant AED medication licensed for monotherapy at baseline (Fig. 2) . The vast majority of patients (n = 85, 91.4%) received only one concomitant AED at baseline, as defined by inclusion criteria; for 7 patients (7.5%), two concomitant AEDs, and for one patient (1.1%), 5 AED were documented.
Five patients were prescribed lacosamide as concomitant AED during the study, which is currently not licensed for monotherapy of POS. The majority of patients (66.7%) had no documented change in their concomitant AED medication during the course of the study. For 16.1%, a withdrawal and/or dose change of a concomitant AED was documented, and for 8.6% a novel prescription of an AED. Considerable differences between younger ( 60 years) and older N describes all patients for whom an entry was provided by the physician (i.e. if entry was 0 the patient was counted), while if no data were entered in a given seizure category, the patient was considered missing for this analysis. (>60 years) patients regarding the intake of concomitant AED medication was observed for levetiracetam (more frequent in older patients), valproate (less frequent in older patients) and oxcarbazepine (no prescription in older patients).
L e v e t i r a c e t a m
Retention of ZNS add-on therapy
For the total population, the 6 month retention rate of ZNS addon therapy was 82.8% (95%-CI: 73.6-89.8%). The retention rate at 3 months was higher with 91.4% (95%-CI: 83.8-96.2%). Subgroup analysis of the 6-month retention rate by age showed a slightly higher retention in patients older than 60 years: 87.5% (95%-CI: [67.6%, 97.3%]) vs. 81.2% (95%-CI: [69.9%, 89.6%]) for patients 60 years (Fig. 3A) (Fig. 3B) .
Reported efficacy
At 3 months, 39.3% of the patients reported to be seizure free, and seizure freedom rate at 6 months was 43.6%. The responder rate (proportion of patients with a reduction of seizure frequency of at least 50%) was 78.8% at 3 months, and 79.7% at 6 months (Fig. 4A) . For all seizure types, a reduction of seizure frequency was observed throughout the study (Fig. 4B) ; the median of total seizure frequency dropped from 6.0 at baseline (see also Table 1 ) to 1.0 at both, the 3-and the 6-months visits.
Correspondingly, overall seizure outcome rated by the physicians at the 6-month follow-up visit was ''good'' or ''very good'' in 77.6% of the patients.
While the responder rate at 3 months was not affected by patients' age, the rate was higher at 6 months in patients older than 60 years than in the younger group (90.0% vs. 75.9%) (not shown).
Responder rates varied considerably with respect to the number of previously discontinued AED regimens. After 6 months, the highest responder rate was observed for patients without any previously discontinued AED (87.5%) and the lowest for the group with !3 AEDs (66.7%). Responder rates for patients with one or two previously discontinued AEDs were 75.0% and 80.0%, respectively.
Quality of life
The QOLIE-10 was completed at baseline by 74 patients, at the 3-month visit by 73 patients, and at the 6-month visit by 65 patients. The mean value of the score declined from 2.8 at baseline to 2.4 at 3 months and to 2.0 at the 6-month visit, with lower values representing better QoL [15] (Fig. 5A) .
While age >60 years and female gender were associated with slightly worse baseline health-related quality of life, after 6 months, QOLIE-10 scores did not differ between the age and gender subgroups (not shown). Similarly, no major influence on QOLIE-10 scores was observed in subgroup analyses by baseline AED and number of previously discontinued AED regimens (not shown). The patients' seizure situation at the final visit (after 6 months) had a significant impact on the improvement of QoL throughout the study. Patients who had become seizure-free after 6 months showed a significantly lower QOLIE-10 score at 6 months than patients for whom the seizure frequency reduction was less than 50% (Fig. 5B) . Statistical significance was determined by means of ANCOVA, with baseline QOLIE-10 level as covariate.
Tolerability
The physicians' overall appraisal of the tolerability of ZNS addon therapy was in most cases ''very good'' (63.1%) or ''good'' (31.0%). For 2 patients, the tolerability of ZNS was assessed as ''poor''-each of these two patients had a documented adverse event (aggression; tremor and nausea) which was considered related to ZNS treatment; for 9 patients, the respective information was missing. The majority (96.1%) of patients in whom ZNS treatment was not discontinued during the study wished to continue treatment with ZNS beyond the study.
Adverse events
Overall, 31 adverse events (AEs) were reported in 18 patients (19.4%), thereof 5 patients (5.4%) with at least one serious AE. 23 adverse drug reactions (ADRs), defined as an AE with a causal relationship to ZNS, were reported in 14 patients (15.1%). For 3 patients (3.2%), an AE was the reason for withdrawal of ZNS Table 1 . For seizure categories, only patients with a corresponding entry were considered for the calculation, i.e. if no entry was provided by the physician for a given seizure category, the patient was considered missing and was not considered for calculation of mean seizure number. For both A and B, the number of seizures during the periods spanning 3 month intervals before each visit are given.
during the study; these AEs were: myalgia, convulsion, contusion, tremor and nausea; in 5 patients (5.3%), ZNS was discontinued during the study due to lack of efficacy. The most frequent AEs with respect to System Organ Class (SOC) were nervous system disorders (8 patients, 8.6%) and psychiatric disorders (6 patients, 6.5%). For the latter 6 patients, the following 7 AEs were reported: impulsive behavior (n = 1), depression (n = 1), agitation (n = 2), dyssomnia (n = 1), psychotic disorder (n = 1), and aggression (n = 1).
The most frequently reported preferred terms (PTs) of AEs were fatigue (3 patients, 3.2%), agitation, dizziness and headache (each 2 patients, 2.2%). Bodyweight loss of 2 kg was reported as an adverse event in one patient.
Discussion
Suffering from epilepsy has a major impact on quality of life, and the treatment and long-term control of epilepsy are challenging [7] . Although the majority of newly diagnosed patients will respond to initial antiepileptic therapy and enter longterm remission, approximately one third of the patients show treatment refractory epilepsy [5] . Thus, achieving seizure freedom or a significant reduction in seizure frequency, while avoiding unacceptable toxicities, represents the goal in the management of epilepsy. Many patients can only achieve this goal with combination therapy [6] . However, the choice of AED combination partners is often difficult due to inacceptable toxicities caused by drug-drug interactions, which in turn lead to dissatisfaction in the patients and low adherence to therapy [7, 8] .
A favorable pharmacokinetic profile of ZNS has been shown in terms of low interaction potential with other AED, which facilitates its use as an adjunctive therapy to achieve better seizure control. Efficacy and safety of ZNS have been extensively proven in controlled clinical settings [10] [11] [12] [13] [14] . In addition, the ZADE observational study showed good responder rates and health related quality of life improvement after 4 months of ZNS adjunctive treatment in clinical practice settings in Germany and Austria [17] . The aim of the present observational study ZOOM was to gather further real world data on ZNS-dosing, retention of treatment, efficacy, health-related quality of life under treatment, as well as tolerability over a period of 6 months, with ZNS given as add-on to a current AED monotherapy.
The majority (82.8%) of patients retained ZNS adjunctive treatment for at least 6 months (Fig. 3A) , and the majority of these patients (96.1%) stated at the last visit that they would wish to continue ZNS treatment beyond the study period. These findings indicate that both patients and physicians were overall satisfied with the treatment outcome. The retention rate is higher than reported in the literature [18] , where 24-week retention of less than 70% was seen. The majority of patients reached their respective target dose within a month, most of them within 2 titration steps. The median daily dose after titration was 200 mg, which was lower than in previous studies [10, 17] . This might indicate that the here observed population was less severely ill and therefore required lower doses of ZNS than the patients included in controlled clinical trials with ZNS [11] [12] [13] [14] .
The relatively short duration of epilepsy, the lower baseline seizure frequency (Table 1 and Fig. 1 ), and the fact that patients were to be on AED monotherapy at baseline, further corroborates this assumption. Within ZOOM, only 18.3% of the patients required dose changes after titration with almost equal distribution of dose increases (47.1%) and reductions (52.9%). Altogether, these findings indicate that adjunctive therapy with ZNS is easy to initiate, maintain and individualize in daily clinical practice.
Assessments of reported efficacy revealed that the majority of patients fulfilled the definition of response (reduction of seizure frequency by !50%) already after 3 months of adjunctive treatment with ZNS, and at 6 months, responder rate was as high as 79.7% (Fig. 4) . In addition, a fair amount (43.6%) of patients reported seizure freedom after 6 months, thus indicating a favorable outcome of ZNS treatment. The low sample size and the observational non-comparative nature of the study do not allow further conclusions regarding efficacy. Nonetheless, the findings are consistent with those from the ZADE non-interventional study [17] , where almost identical seizure outcome rates were reported after 4 months of ZNS adjunctive therapy. Correspondingly, the physicians' assessment of overall seizure outcome after 6 months was good or very good in more than 75% of the patients within the present observational study ZOOM. Quality of life assessed by means of the QOLIE-10 questionnaire improved after 6 months of ZNS adjunctive treatment in mean by 22.2% (AE27.7%, SD). In line with previous findings [19] , subgroup analysis according to the seizure-outcome after 6 months showed that patients who became seizure free during the study reported a significant improvement in QoL, which could not be observed in patients whose seizure frequency was not reduced by at least 50% (Fig. 5) . Importantly, for these non-responders, stable QoL scores in the course of the study indicate that ZNS treatment did not negatively affect quality of life Previous studies have shown a negative impact of drugrefractoriness of epilepsy on effectiveness of antiepileptic treatment regimens [6, 16] . Schiller and Najjar used the number of previously discontinued AED regimens for classifying the stage of drug-refractoriness of the disease. They observed that patients with more discontinued (i.e. inefficient) treatment regimens for epilepsy were less likely to achieve seizure freedom or meaningful seizure frequency reduction with a novel AED regimen [16] . A subgrouping-approach was used in the present study as well, where patients were classified for drug-refractoriness of epilepsy according to the number of discontinued AED regimens over the period of 5 years prior to inclusion. These subgroups did not display any major differences of their retention rates at 6 months. However, indeed patients with 3 or more previously discontinued AEDs showed the lowest responder rate at 6 months, while patients without any previous AED regimen showed the highest (66.7 vs. 87.5% respectively). This confirms previous studies, which reported a strong negative correlation between the chance for seizure freedom under a given AED and the number of AED tried in the past [16] .
In order to assess if AED medication at baseline potentially affected outcome, subgroup analyses by baseline AEDs were performed. Four major subgroups according to concomitant AED medication at baseline were identifiable within the ZOOM NIS population: carboxamide derivatives, levetiracetam, lamotrigine, and valproate. Retention rates were high within all groups, with patients receiving levetiracetam or valproate having the lowest (78.6% and 78.9% respectively), and carboxamide derivatives or lamotrigine (88.0% and 92.9%, respectively) displaying the highest (Fig. 3B) . Although the low number of patients in each subgroup prohibits conclusions, it seems noteworthy that the concomitant AED treatment also seemed to be associated with variations in efficacy in terms of responder rate at 6 months, with the proportion of responders ranging from 66.7% in the valproate group to 91.7% in the lamotrigine group. In addition, the choice of baseline AED seemed to be influenced by the patients' age, with a considerably higher amount of patients taking levetiracetam as a combination partner of ZNS in the group of patients older than 60 years (45.8%), as compared to patients 60 years or younger (27.5%) (Fig. 2) . This finding somewhat contrasts with previous observations [20] , where levetiracetam was preferably prescribed to younger patients, and once again might reflect the poor sample size in the present study. Nonetheless, these findings may deserve attention as they might hint towards a differential benefit of ZNS as adjunctive therapy according to the choice of AED combination partner, but also that this choice might be affected by the patients' age in a real-world setting. In this context, the relatively high proportion of patients older than 60 years within the present study also deserves attention; the fact that the mean duration since diagnosis of epilepsy was lower in these patients compared to the younger group points towards a relatively higher proportion of patients with late-onset epilepsy in the present study. For patients in this older subgroup, mean ZNS dosing post-titration was lower than for the younger patients (185.3 AE 47.7 vs. 229.2 AE 111.0 mg/d), while retention rate, reported efficacy and improvement of QoL were relatively higher. These findings underline the importance of observational studies with less stringent inclusion criteria regarding the patients' age, and might hint towards age-dependent therapeutic criteria in everyday clinical practice.
The evaluation of tolerability for ZNS as only add-on therapy within ZOOM was overall positive. It was rated good or very good by the physicians in 94.0% of the patients. Patients were withdrawn from the study due to an adverse event only in 3 cases, and due to lack of efficacy in 5. The majority of the reported adverse events were non-serious, yet mostly considered related to ZNS treatment. Importantly, the rates of adverse events considered related to ZNS treatment seemed independent of the drug class of concomitant AED medication. As in previous studies [10] , fatigue, headache, dizziness and sleep disorders were among the most frequently reported adverse events.
The major limitation of the presents study was, that due to slow recruiting, only 100 patients could be included. Thus, the generalisability of the obtained results, while promising, is limited due to the low sample size of 93 evaluable patients.
Conclusion
Taken together, the results of the present observational study ZOOM are in accordance with previous findings that ZNS may be efficacious and well tolerated as adjunctive therapy in patients with partial-onset seizures poorly controlled with AED monotherapy. The present data also hints at beneficial effects of ZNS adjunctive therapy on QoL, and may thus further strengthen the role of adjunctive ZNS therapy. Further, due to its low interaction profile, ZNS appears to be easily combinable with a broad spectrum of AEDs currently used for management of POS, thus representing a useful therapeutic option in everyday clinical use.
